Alnylam s Underwriters Exercise Over-Allotment Option | GenomeWeb

NEW YORK, June 7 (GenomeWeb News) - Underwriters of Alnylam Pharmaceuticals' initial public offering have exercised an over-allotment option, the company said today.


The underwriters have purchased an additional 750,000 shares of common stock at the IPO price of $6 per share, less an underwriting discount of $.42 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.